Pharmaceuticals company Cipla announced Q2FY25 results Financial Highlights: Highest-ever quarterly Revenue and EBITDA margin at 26.7%. Income from Operations: Rs 7,051 crore, change 9% YoY. EBITDA: Rs 1,886 crore, change 12% YoY. EBITDA margin: 26.7%. PAT: Rs 1,303 crore, change 17% YoY. PAT Margin: 18.5%. Business Highlights: One India Business grew at 5% YoY. Branded Prescription business continued to outpace the market in key Chronic therapies. CHL delivered strong growth at 21% YoY. The business however, witnessed a historically slow seasonal growth in Acute category impacting both Branded Prescription and Trade Generics business. Delivered quarterly revenue of USD 237 million up by 4% YoY supported by traction in differentiated portfolio. Progressing on the journey of strengthening the Africa story, the North Africa business which was a part of Emerging markets and Europe is now merged with SAGA region which is renamed as One Africa. Momentum continues with overall revenue growth at 22%. Emerging Markets and Europe: Posted a robust revenue growth of 18% in USD terms. R&D; investments: stand at INR 385 crore or 5.5% of sales, higher by 2% YoY driven by product filings and developmental efforts. Net cash position of Rs 7,950 crore; Debt primarily includes lease liabilities and working capital requirements. Umang Vohra MD and Global CEO, Cipla, said: “I am pleased to share that we continue to make considerable progress across our focused markets. In Q2FY25, we recorded a revenue growth of 9% over last year with a highest-ever EBITDA margin of 26.7%, driven by mix and other operational efficiencies. Our One-India business was impacted during the quarter due to changed seasonal pattern, however key chronic therapies in Branded Prescription business continued to grow faster than the market. Consumer health business grew at a strong 21% YoY. With our concentrated focus in differentiated portfolio, the US business posted a revenue of USD 237 million. In South Africa, we recorded a solid growth of 22% YoY in local currency terms, led by Private Market. Emerging Markets and Europe delivered a robust revenue growth of 18% YoY on the back of deep market focus strategy. Going ahead, focus will be on growing our key markets, further building our flagship brands, investing in future pipeline as well as focusing on resolutions on the regulatory front”. Result PDF